Carboplatin is a second-generation platinum antineoplastic compound. After entering cells, it forms reactive platinum complexes that bind to DNA and produce intra- and interstrand DNA cross-links. These changes interfere with DNA replication and repair, inhibit cancer-cell proliferation, and can ultimately lead to cancer-cell death.
It may be prescribed for:
Clinical research and evidence:
Carboplatin is used as an antineoplastic medication. Its established indication includes initial treatment of advanced ovarian carcinoma in combination with other approved chemotherapy agents and palliative treatment of recurrent ovarian carcinoma following previous chemotherapy.
Carboplatin is also used in various combination chemotherapy protocols for other cancers. Specific use depends on the tumor type, stage, treatment history, and applicable oncology guidelines.
Its anticancer action is based on DNA damage. Platinum complexes formed from carboplatin interfere with DNA structure, replication, and repair, thereby inhibiting cancer-cell growth.
The medication is administered intravenously in a medical setting. The treating physician determines the individual dose and treatment interval based on the diagnosis, chemotherapy regimen, kidney function, blood counts, and treatment tolerance. Blood tests and other clinical assessments are required during treatment because carboplatin can cause significant bone marrow suppression. It must not be self-administered or used outside a prescribed oncology treatment protocol.
